Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 60 | 3,423 | 48% |
| 2020 | 66 | 3,234 | 50% |
| 2021 | 62 | 3,383 | 52% |
| 2022 | 57 | 3,393 | 53% |
| 2023 | 52 | 3,431 | 55% |
| 2024 | 71 | 3,581 | 56% |
| 2025 from claims | – | 3,886 3,566–4,111 | 56% |
| 2026 forecast | – | 4,020 3,537–4,639 | 56% |
| 2027 forecast | – | 4,133 3,534–4,926 | 56% |
| 2028 forecast | – | 4,250 3,546–5,204 | 56% |
| 2029 forecast | – | 4,370 3,569–5,481 | 57% |
| 2030 forecast | – | 4,493 3,600–5,758 | 57% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 33% of the cases CMS names in California; 47 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 38% inpatient hospital, 62% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~4,000 | ~1,500 | ~2,500 |
| 2027 · ~4,100 | ~1,500 | ~2,600 |
| 2028 · ~4,300 | ~1,500 | ~2,700 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 36% (38% in 2025), hospital outpatient about 64% (62% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 14 | 942−0.8%/yr | −0.8%/yr | 1.4 | 0% | 1,200 in 2030+4.1%/yr |
| Washington | 17 | 909−2.1%/yr | −2.1%/yr | 1.3 | 0% | 790 in 2030−2.3%/yr |
| Colorado | 9 | 636−1.1%/yr | −1.1%/yr | 1.4 | 0% | 690 in 2030+1.4%/yr |
| Oregon | 10 | 568−2.4%/yr | −2.4%/yr | 1.5 | 0% | 610 in 2030+1.2%/yr |
| Utah | 3 | 285+1.5%/yr | +1.5%/yr | 1.4 | 0% | 440 in 2030+7.5%/yr |
| Idaho | 5 | 276+4.7%/yr | +4.7%/yr | 1.5 | 0% | 260 in 2030−1.1%/yr |
| Montana | 6 | 237−1%/yr | −1%/yr | 1.3 | 0% | 280 in 2030+2.8%/yr |
| Nevada | 4 | 227−1.5%/yr | −1.5%/yr | 0.9 | 0% | 510 in 2030+14%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 202 | 14,148−8%/yr | −8%/yr | 4.20.8× | 48% | 14,100 in 2030−0.1%/yr |
| Kidney stone management | 210 | 10,020+0.3%/yr | +0.3%/yr | 3.00.7× | 17% | 11,600 in 2030+2.5%/yr |
| Hysterectomy, hysteroscopy & ablation | 85 | 6,904+1.6%/yr | +1.6%/yr | 2.30.9× | 25% | 7,960 in 2030+2.4%/yr |
| Incontinence, prolapse & sacral neuromodulation | 73 | 5,242+0.1%/yr | +0.1%/yr | 1.60.7× | 20% | 6,070 in 2030+2.5%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Intuitive Surgical leads with 98% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with California’s surgeons worth $1.0M in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.